Table 2 CAR-T cell therapy in ongoing clinical trials
From: Characteristics of the cancer stem cell niche and therapeutic strategies
Target | Tumor type | Phase | Study number |
|---|---|---|---|
CD19 | Relapsed/refractory B-ALL | Phase 2 | NCT05334823 |
Relapsed/refractory leukemia/lymphoma | Phase 1 | NCT03984968 | |
CD19/CD22 | Non-Hodgkin lymphoma | Phase 1 | NCT05098613 |
CD30 | Relapsed/refractory Hodgkin lymphoma | Phase 2 | NCT04268706 |
CD33 | Acute myeloid leukemia | Phase 1/2 | NCT03971799 |
CD38 | Acute myeloid leukemia | Phase 1 | NCT05239689 |
CD70 | Pancreatic/renal/breast cancer | Phase 1/2 | NCT02830724 |
CD123 | Acute myeloid leukemia | Phase 1 | NCT04230265 |
CD171 | Neuroblastoma | Phase 1 | NCT02311621 |
c-Met/PD-L1 | Hepatocellular carcinoma | Phase 1 | NCT03672305 |
EpCAM | Pancreatic/gastric/colorectal cancer | Phase 1 | NCT05028933 |
GD2 | Neuroblastoma | Phase 1 | NCT01822652 |
GPC3 | Liver cancer | Phase 1 | NCT02932956 |
Hepatocellular carcinoma | Phase 1 | NCT02905188 | |
MOv19-BBz | Ovarian/fallopian tube/peritoneal cancer | Phase 1 | NCT03585764 |
P-MUC1C-ALLO1 | Advanced or metastatic solid tumors | Phase 1 | NCT05239143 |
IL13Rα2 | Brain tumor | Phase 1 | NCT04661384 |